News and Community

Adjuvant Therapy, Astrazeneca, Daiichi Sankyo, Destiny-endometrial02, Endometrial Cancer, Enhertu, Future Of Oncology, Her2, Phase 3 Trial

December 22, 2025

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU Started as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer